 Connection
Elizabeth David to Neoplasm Staging
This is a "connection" page, showing publications Elizabeth David has written about Neoplasm Staging.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.346 |
|
|
|
-
Toubat O, Ding L, Ding K, Wightman SC, Atay SM, Harano T, Kim AW, David EA. Benefit of adjuvant chemotherapy for resected pathologic N1 non-small cell lung cancer is unrecognized: A subgroup analysis of the JBR10 trial. Semin Thorac Cardiovasc Surg. 2024 Summer; 36(2):261-270.
Score: 0.652
-
Toubat O, Atay SM, Kim AW, Ding L, Farias AJ, Ebner PJ, McFadden PM, David EA. Disparities in Guideline-Concordant Treatment for Pathologic N1 Non-Small Cell Lung Cancer. Ann Thorac Surg. 2020 05; 109(5):1512-1520.
Score: 0.539
-
David EA, Cooke DT, Chen Y, Nijar K, Canter RJ, Cress RD. Does Lymph Node Count Influence Survival in Surgically Resected Non-Small Cell Lung Cancer? Ann Thorac Surg. 2017 Jan; 103(1):226-235.
Score: 0.423
-
David EA, Andersen SW, Beckett LA, Melnikow J, Clark JM, Brown LM, Cooke DT, Kelly K, Canter RJ. Survival benefits associated with surgery for advanced non-small cell lung cancer. J Thorac Cardiovasc Surg. 2019 04; 157(4):1620-1628.
Score: 0.124
-
David EA, Andersen SW, Beckett LA, Melnikow J, Kelly K, Cooke DT, Brown LM, Canter RJ. A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients. Ann Thorac Surg. 2017 Nov; 104(5):1665-1672.
Score: 0.115
-
David EA, Daly ME, Li CS, Chiu CL, Cooke DT, Brown LM, Melnikow J, Kelly K, Canter RJ. Increasing Rates of No Treatment in Advanced-Stage Non-Small Cell Lung Cancer Patients: A?Propensity-Matched Analysis. J Thorac Oncol. 2017 03; 12(3):437-445.
Score: 0.109
-
David EA, Canter RJ, Chen Y, Cooke DT, Cress RD. Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival. Ann Thorac Surg. 2016 Oct; 102(4):1101-9.
Score: 0.105
-
Cooke DT, Gandara DR, Goodwin NC, Calhoun RF, Lara PN, Mack PC, David EA. Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer. J Thorac Cardiovasc Surg. 2014 Jul; 148(1):36-40.
Score: 0.090
-
Dyas AR, Bronsert MR, Stuart CM, Thomas MB, Schulick RD, Franco SR, Gleisner A, Randhawa SK, David EA, Mitchell JD, Meguid RA. Analyzing the impact of the Coronavirus disease 2019 pandemic on initial oncologic presentation and treatment of non-small cell lung cancer in the United States. J Thorac Cardiovasc Surg. 2024 Aug; 168(2):378-390.e7.
Score: 0.044
-
Kidane B, Bott M, Spicer J, Backhus L, Chaft J, Chudgar N, Colson Y, D'Amico TA, David E, Lee J, Najmeh S, Sepesi B, Shu C, Yang J, Swanson S, Stiles B. The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer. J Thorac Cardiovasc Surg. 2023 09; 166(3):637-654.
Score: 0.043
-
Wightman SC, Lee JY, Ding L, Atay SM, Shemanski KA, McFadden PM, David EA, Kim AW. Adjuvant chemotherapy for visceral pleural invasion in 3-4-cm non-small-cell lung cancer improves survival. Eur J Cardiothorac Surg. 2022 06 15; 62(1).
Score: 0.040
-
Zhao J, Nguyen A, Ding L, David EA, Atay SM, Wightman SC, McFadden PM, Kim AW. Trends in pneumonectomy for treatment of small-cell lung cancer. Asian Cardiovasc Thorac Ann. 2020 Nov; 28(9):583-591.
Score: 0.035
-
Bateni SB, David EA, Bold RJ, Cooke DT, Meyers FJ, Canter RJ. Lung resection is safe and feasible among stage IV cancer patients: An American College of Surgeons National Surgical Quality Improvement Program analysis. Surgery. 2017 05; 161(5):1307-1314.
Score: 0.027
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|